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A B S T R A C T
Colorectal cancer (CRC) is the third most common cancer in economically developed countries and a major cause
of cancer-related mortality. The importance of lifestyle and diet as major determinants of CRC risk is suggested
by diﬀerences in CRC incidence between countries and in migration studies. Previous observational epidemio-
logical studies have identiﬁed associations between modiﬁable environmental risk factors and CRC, but these
studies can be susceptible to reverse causation and confounding, and their results can therefore conﬂict.
Mendelian randomisation (MR) analysis represents an approach complementary to conventional observational
studies examining associations between exposures and disease. The MR strategy employs allelic variants as
instrumental variables (IVs), which act as proxies for non-genetic exposures. These allelic variants are randomly
assigned during meiosis and can therefore inform on life-long exposure, whilst not being subject to reverse
causation. In previous studies MR frameworks have associated several modiﬁable factors with CRC risk, in-
cluding adiposity, hyperlipidaemia, fatty acid proﬁle and alcohol consumption. In this review we detail the use
of MR to investigate and discover CRC risk factors, and its future applications.
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers in
economically developed countries and a major cause of cancer-related
mortality (Forman et al., 2014). The disease is currently diagnosed in
over one million individuals worldwide annually; although its in-
cidence is set to rise in developing countries with the adoption of
western lifestyles and diets (Haggar and Boushey, 2009). The im-
portance of lifestyle and diet as major determinants of CRC risk have
been strongly suggested by geographical diﬀerences in CRC incidence
and demonstrated in migration studies (Kamangar et al., 2006). Given
the importance of these factors in CRC risk, the modiﬁcation of lifestyle
and diet through public health initiatives oﬀers the prospect of sig-
niﬁcant impact on CRC incidence. The full compendium of exposures
aﬀecting CRC risk, and their relative contributions, has yet to be elu-
cidated however, necessitating further work to discover and validate
risk factors.
2. Established and postulated colorectal cancer risk factors
Both environmental and genetic factors play important roles in CRC
aetiology. The majority of CRCs are sporadic, with approximately 80%
of patients presenting without a family history of the disease (Winawer
et al., 1997). The lifetime risk for CRC in Western populations is ap-
proximately 4% (Siegel et al., 2017), although this risk is almost dou-
bled in individuals with a ﬁrst-degree family member diagnosed with
CRC, and tripled in individuals with two or more aﬀected family
members (Taylor et al., 2010). Epidemiological studies have provided
support for a hereditary component to the aetiology of a large number
of cancers, including CRC (Risch, 2001). For many cancers, a higher
concordance in monozygotic twins as compared with dizygotic twins,
or with siblings, has been observed (Lichtenstein et al., 2000). Whilst
such concordance is compatible with inherited genetic variation af-
fecting risk, non-genetic mechanisms cannot be excluded as a basis of
the measured heritability.
Technological developments in high-throughput genotyping and
improved understanding of common genetic variation have made
genome-wide association studies (GWAS) possible, facilitating the
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identiﬁcation of single nucleotide polymorphisms (SNPs) inﬂuencing
cancer risk (Sud et al., 2017). So far, GWAS have identiﬁed approxi-
mately 100 SNPs independently associated with CRC risk (Al-Tassan
et al., 2015; Broderick et al., 2007; Cogent Study et al., 2008; Dunlop
et al., 2012; Houlston et al., 2010; Kinnersley et al., 2012; Orlando
et al., 2016; Schumacher et al., 2015; Tenesa et al., 2008; Tomlinson
et al., 2007; Whiﬃn et al., 2014), with the largest study to-date com-
bining data from over 125,000 individuals (Huyghe et al., 2019). The
identiﬁcation of these risk variants has contributed to an improved
understanding of the pathways and mechanisms inﬂuencing CRC de-
velopment.
Multiple lifestyle and environmental factors, many of which are
modiﬁable, are now known to inﬂuence CRC risk (Kuipers et al., 2015;
World Cancer Research Fund, 2017). The World Cancer Research Fund
(2017) conducted a systematic analysis of known and suspected CRC
risk factors, categorizing them into those with strong and limited evi-
dence for a causal relationship. The evidence that obesity, height, al-
cohol intake and consumption of red and processed meats increases
CRC risk was reported as strong, whilst the evidence that low intake of
non-starchy vegetables and fruits, and high intake of foods containing
iron increases CRC risk was reported to be weaker. The World Cancer
Research Fund report also highlighted physical activity, the consump-
tion of whole grains, ﬁbre, dairy products and the use of calcium sup-
plements as being strongly associated with lower CRC risk, but reported
weaker evidence that use of multivitamin supplements, and high intake
of foods containing vitamins C and D similarly decreases CRC risk.
Increased CRC risk has also been associated with chronic colitis due
to inﬂammatory bowel disease (IBD) (Lu et al., 2018). The longer the
duration of IBD, the greater the increase in CRC risk (Lu et al., 2018).
However, whilst IBD is thought to increase risk of CRC, it explains only
a small proportion of CRC incidence in Western populations (Kuipers
et al., 2015). Improved surveillance and the increasing eﬀectiveness of
anti-inﬂammatory treatments may also be lowering the incidence of
CRC in those with IBD (Jess et al., 2012). Heavy smoking over a pro-
longed period has also been recognised as being associated with in-
creased CRC risk, in the region of an additional 11 cases per 100,000
person-years (Botteri et al., 2008).
The inﬂuence of modiﬁable environmental and lifestyle risk factors
is likely to partly explain the socioeconomic and geographic diﬀerences
in CRC rates (Doubeni et al., 2012). It has been estimated that as many
as 71% of CRCs in Western countries may be due to these modiﬁable
exposures and therefore preventable (Platz et al., 2000). However, to
reduce CRC incidence through public health initiatives, it is imperative
to determine which factors associated with CRC risk are causally re-
lated, and which are simply correlated.
3. Approaches for risk factor discovery and validation
3.1. Observational epidemiological studies
So far, many studies attempting to evaluate relationships between
possible risk factors and diseases, such as CRC, have relied upon ob-
servational case-control, cohort, or cross-sectional study designs
(Lawlor et al., 2004). Whilst observational studies have seemingly ro-
bustly associated a risk factor and a disease, interventions modifying
such risk factors do not always result in the anticipated change in dis-
ease incidence (Davey Smith and Hemani, 2014). A number of ex-
planations for these ostensibly paradoxical observations have been
suggested, including the susceptibility of observational epidemiological
studies to certain biases, such as reverse causation, confounding and
errors in measurement. These biases can result in an apparent asso-
ciation between a risk factor and a disease, without the existence of a
direct causal relationship.
Reverse causation occurs when the postulated risk factor does not
itself inﬂuence disease development, but instead the occurrence of the
disease aﬀects the postulated risk factor. An example of possible reverse
causation is in the relationship between computerized tomography (CT)
scans and cancer (Mathews et al., 2013). Higher cancer incidence has
been observed in individuals exposed to low-dose ionizing radiation
from diagnostic CT scans (Mathews et al., 2013). However, it is diﬃcult
to exclude the possibility that the symptoms of precancerous condi-
tions, or early cancer symptoms, led to patients having CT scans. Ret-
rospective studies that seek to establish risk factors after disease diag-
nosis are especially susceptible to such reverse causation.
Confounders are factors causally related to both the postulated risk
factor and the disease under consideration. For instance, smoking has
been associated with increased risk of CRC (Botteri et al., 2008).
However, smoking may be associated with other CRC risk factors, in-
cluding alcohol consumption, physical inactivity and low uptake of CRC
screening (Chao et al., 2000). An individual who consumes more al-
cohol is indeed more likely to smoke, and if alcohol consumption is
causally related to CRC development, then this confounder could partly
explain the association between smoking and CRC incidence. Such
confounders are not always measured in observational epidemiological
studies, and it may therefore not be possible to control for them when
evaluating risk factors. Furthermore, unidentiﬁed confounders may
exist, resulting in additional bias that could be impossible to account for
in a traditional observational study design.
3.2. Mendelian randomisation
The gold standard for inferring causality is a randomized control
trial (RCT). Individuals in an RCT are randomly assigned to two or more
groups, minimizing both selection bias and confounding. As groups are
assigned at the start of the study, reverse causation can be avoided.
RCTs are however often not possible due to the costs or the time re-
quired. Furthermore, RCTs can have short follow-up times and hence
only reﬂect the eﬀect of an exposure at a certain time in life. It is also
not always possible to assign individuals to groups to evaluate certain
risk factors because of practical or ethical concerns.
Mendelian randomisation (MR) uses genetic variants, such as SNPs,
as proxies for exposures to determine the eﬀect of an exposure on an
outcome (Sheehan et al., 2008). In the general population, germline
variants tend to be randomly distributed with respect to most human
traits. This occurs because of the ﬁxed nature of germline genotypes
and Mendel's laws of inheritance (i.e. segregation and independent as-
sortment). Using germline variants as proxies for an exposure therefore
ensures that MR is less susceptible to biases that aﬀect many observa-
tional epidemiological studies (Davey Smith and Hemani, 2014). For
example, as genotypes are randomly assigned at conception, MR is not
biased by reverse causation. MR can therefore be considered analogous
to a natural RCT. Furthermore, as genotypes are present at conception,
MR analyses can examine the lifetime eﬀect of an exposure on disease
risk, unlike other study designs.
MR analyses involve three main assumptions: (i) the genetic var-
iants used as IVs are robustly associated with the exposure under con-
sideration; (ii) these IVs are independent of confounding factors; and
(iii) the IVs are only associated with the outcome under consideration
via the exposure (Lawlor et al., 2008). These three assumptions are
often depicted as a directed acyclic graph (Fig. 1). The satisfaction of
these three assumptions is suﬃcient to test the null hypothesis that the
exposure is not causally related to the outcome. However, to accurately
estimate the size of the eﬀect, a fourth additional assumption is re-
quired: (iv) all associations depicted in Fig. 1 are unaﬀected by statis-
tical interactions and are linear (Lawlor et al., 2008). Considering these
assumptions, genetic variants can be used as proxies for a large range of
modiﬁable risk factors. In one-sample MR, a single data set containing
all information on the genetic variants, the exposure and the outcome
for all individuals is used to assess a potential causal relationship
(Haycock et al., 2016). In practice, few data sets contain exposure data
for all individuals and a suﬃcient number of disease cases and controls
to conduct one-sample MR analyses with suﬃcient power to identify
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causal eﬀects. This has prompted the development of two-sample MR
strategies, which use data from separate data sets: one containing in-
formation on genetic variants and the exposure of interest, and another
containing information on the same genetic variants and the considered
outcome (Hartwig et al., 2016). For many risk factors and cancers,
GWAS containing data from tens or hundreds of thousands of in-
dividuals have been completed (Sud et al., 2017), facilitating the use of
two-sample MR to study the causal relationship between various ex-
posures and diseases. Resources such as the GWAS Catalog have col-
lated and standardized data from a large number of studies (Buniello
et al., 2019), aiding the identiﬁcation of suitable genetic instruments.
One of the central tenets of MR is the absence of pleiotropy (i.e. a
variant inﬂuencing multiple traits) between the SNPs associated with
the exposure and outcome (Davey Smith and Hemani, 2014). Direc-
tional pleiotropy can result in the false identiﬁcation of an association
between a putative exposure and outcome, or the failure to identify a
true causal relationship (Burgess and Thompson, 2017). Multiple
methods have been developed to assess whether such directional
pleiotropy exists and avoid it biasing causal estimates. In MR-Egger
regression, the slope coeﬃcient from Egger regression is used to assess
directional pleiotropy (Bowden et al., 2015). MR-Egger regression relies
on the assumption that the pleiotropic eﬀects of each variant are in-
dependently distributed from the genetic association with the outcome;
an assumption referred to as InSIDE (INstrument Strength Independent
of Direct Eﬀect). If the InSIDE assumption is satisﬁed, then MR-Egger
causal eﬀect estimates will be consistent as sample size and the number
of genetic variants increase (Burgess and Thompson, 2017). Further-
more, under the InSIDE assumption the MR-Egger intercept term can be
used to evaluate the average pleiotropic eﬀect across variants. If this
average pleiotropic eﬀect is zero, then the MR-Egger causal eﬀect es-
timate will equal causal eﬀect estimates from other regression-based
MR approaches, including the inverse variance weighted (IVW) method
(Burgess and Thompson, 2017).
Approaches such as the HEIDI outlier test, implemented as part of
the Generalised Summary-data-based Mendelian Randomisation
(GSMR) package (Zhu et al., 2018), can also be used to identify and
remove variants that violate IV assumptions. Methods such as simple
and weighted median estimators (Bowden et al., 2016) and the mode-
based estimate (Hartwig et al., 2017) can produce unbiased estimates of
a causal eﬀect even when the majority of IVs are invalid. Further
methodological developments, such as latent causal variable (LCV)
models, allow for accurate inference of causal relationships, even when
the exposure and outcome are genetically correlated (O'Connor and
Price, 2018). These methods also have their disadvantages however,
with MR-Egger, median estimators and mode-based estimates generally
achieving less power than conventional IV approaches (Bowden et al.,
2015), and LCV models requiring genome-wide summary statistics for
both the exposure and outcome – data that are not always available.
4. Limitations of Mendelian randomisation
Whilst MR analyses complement observational epidemiological
studies, and are less inﬂuenced by some biases, there are a number of
limitations to the approach. MR methods rely on the availability of
genetic instruments robustly associated with the exposure of interest
that can be used as proxies. For some exposures, such as obesity and
height, GWAS containing data from hundreds of thousands of in-
dividuals have been completed, resulting in the identiﬁcation of hun-
dreds of exposure-associated SNPs that explain a high proportion of the
genetically associated exposure (Yengo et al., 2018). For other ex-
posures no or few associated SNPs have been identiﬁed, thereby pro-
hibiting their study using MR frameworks. If exposure-associated SNPs
have been identiﬁed, but these SNPs explain only a small proportion of
exposure variation, then MR analyses may not be suﬃciently powered
to detect causal eﬀects, especially if the true eﬀect sizes are weak
(Smith and Ebrahim, 2004).
The study of some risk factors requires additional information not
always available, even when using a two-sample MR framework. For
example, diﬀerent SNPs are associated with smoking initiation and
number of cigarettes smoked per day (Tobacco and Genetics
Consortium, 2010), and it is therefore necessary to stratify disease cases
and controls by whether they have ever smoked to accurately estimate
the eﬀect size of smoking on disease risk. In many cancer GWAS,
smoking status is not measured, prohibiting the accurate assessment of
eﬀect size.
Although implemented in a number of studies (Ahmad et al., 2015;
Gage et al., 2017), conventional IV approaches in a two-sample setting
may not accurately estimate the eﬀect size of a binary exposure, such as
smoking initiation, on a binary outcome, such as disease diagnosis.
Through simulation we previously evaluated whether IVW, weighted
median estimators, mode-base estimates and MR-Egger methods pro-
vide reliable estimates of causal eﬀects when considering binary ex-
posures and binary outcomes (Disney-Hogg et al., 2018). When a causal
relationship was simulated, the magnitudes of the eﬀect estimates were
inﬂated, and two-sample MR frameworks may therefore not be suitable
for assessing the eﬀect size of binary exposures on CRC risk.
5. Mendelian randomisation in colorectal cancer research
Many studies have implemented two-sample MR frameworks to
evaluate causal relationships between risk factors and CRC. Here we
discuss ﬁndings and insights from these studies (Table 1).
Several studies have investigated the causal relationship between
obesity-related factors and CRC risk. In a study of 9254 CRC cases and
18,386 controls, Jarvis et al. (2016) associated body mass index (BMI)
(OR: 1.23, 95% CI: 1.02–1.49, P=0.033), childhood obesity (OR: 1.07,
95% CI: 1.03–1.13, P=0.018) and waist-hip ratio (WHR) (OR: 1.59,
95% CI: 1.08–2.34, P=0.019) with increased CRC risk. Gao et al.
(2016) similarly associated adult BMI with increased CRC risk (OR:
1.39, 95% CI: 1.06–1.82, P=0.016), but did not ﬁnd signiﬁcant as-
sociations for childhood BMI or WHR, possibly due to the smaller size of
their study, which contained 5100 CRC cases and 4831 controls. Many
obesity-related traits have strong genetic correlations (Bulik-Sullivan
et al., 2015) and further work is therefore necessary to investigate
which aspects of adiposity have the greatest inﬂuence on CRC risk.
It has been suggested that adiponectin, an adipocyte-derived pep-
tide hormone, may mediate the association between obesity and risk of
CRC (Vansaun, 2013). Observational epidemiological studies of adi-
ponectin have however yielded inconsistent results, with some asso-
ciating lower circulating adiponectin with increased CRC risk
(Aleksandrova et al., 2012), and others failing to identify such asso-
ciation (Stocks et al., 2008). MR analyses of adiponectin and CRC risk
have also been inconsistent. In a multi-ethnic meta-analysis, Pei et al.
(2015) considered ﬁve ADIPOQ polymorphisms, ﬁnding the genotype of
one (rs2241766) to be associated with CRC risk (OR: 1.26, 95% CI:
Fig. 1. The basic instrumental variable (IV) model depicted using a di-
rected acyclic graph. Z: the instrumental variable, X: the exposure of interest
(such as a putative risk factor), Y: the outcome of interest (such as a disease), U:
one or more measured or unmeasured confounders.
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1.09–1.47, P= 0.002). Nimptsch et al. (2017) created an ADIPOQ allele
score explaining approximately 3% of the variation in circulating adi-
ponectin, but did not ﬁnd this to be signiﬁcantly associated with CRC
risk. Song et al. (2015) considered 19 adiponectin-associated SNPs and
similarly did not ﬁnd any to be signiﬁcantly associated with the risk of
CRC. Inconsistencies between the observational epidemiological and
MR studies could be due to reverse causation or confounding factors
biasing the observational studies, or because of the relatively low power
of the MR analyses to identify a causal relationship.
Hyperinsulinemia has also been suggested to be associated with
increased risk of CRC. Nimptsch et al. (2015b) therefore used an MR
framework to investigate whether fetuin-A, a liver protein known to
inhibit the action of insulin, was causally related to CRC risk. No sig-
niﬁcant association was identiﬁed, although the analysis contained only
456 case-control pairs, and a small eﬀect of fetuin-A on CRC risk
therefore cannot be excluded.
Development of CRC has been positively correlated with circulating
levels of plasma cholesterol and other components of the lipid proﬁle in
prospective epidemiological studies (Yao and Tian, 2015). It is not clear
however whether these ﬁndings reﬂect a causal relationship or are the
consequence of confounding by factors such as a common aetiology of
both hyperlipidaemia and CRC. Lipid levels can be modiﬁed by both
treatment with statins and lifestyle changes and an understanding of the
causal relationship with CRC is therefore important when developing
CRC prevention programs. The eﬀect of statins, which reduce circu-
lating cholesterol levels, on CRC risk is highly controversial, with a
recent meta-analysis of eight RCTs failing to identify a signiﬁcant
beneﬁcial eﬀect (Lytras et al., 2014). Other analyses have however
associated statin usage with lower CRC incidence (Mamtani et al.,
2016). Rodriguez-Broadbent et al. (2017) employed MR frameworks to
study the eﬀects of blood levels of total cholesterol (TC), triglycerides
(TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
on CRC risk. Higher concentrations of TC were associated with an in-
creased risk of CRC (OR: 1.46, 95% CI: 1.20–1.79, P=1.68×10−4).
Furthermore, a genetic risk score for HMGCR, simulating the eﬀect of
statins, was associated with reduced CRC risk (OR: 0.69, 95% CI:
0.49–0.99, P=0.046) (Rodriguez-Broadbent et al., 2017). This study
therefore supports a causal relationship between TC and CRC risk,
providing further evidence that statin use could be eﬀective in public
health strategies aiming to reduce CRC incidence.
Dietary fat has been implicated as a cancer risk factor, with meta-
analyses of epidemiological studies tending to associate higher con-
sumption of red and processed meat with increased CRC risk (Aykan,
2015). It is unlikely however that the relationship between fat intake
and CRC risk depends solely on the quantity, but also on the speciﬁc
fatty acid (FA) type. Epidemiological studies and animal models have
implicated animal fat (Reddy, 2002), some omega-6 polyunsaturated
fatty acids (PUFAs) and saturated fatty acid (SFA) with increased cancer
risk, and omega-3 PUFA consumption with reduced cancer risk (Azrad
et al., 2013). The evidence of a causal relationship between the con-
sumption of speciﬁc fatty acids from observational epidemiological
studies has however been inconclusive. Possible reasons for this include
reverse causation, confounding factors and inaccurate measurement of
long-term diet (Theodoratou et al., 2007). Results from an MR study by
May-Wilson et al. (2017) were broadly consistent with a pro-in-
ﬂammatory FA proﬁle having a detrimental eﬀect on risk of CRC.
Arachidonic acid (OR: 1.05, 95% CI: 1.02–1.07, P=1.7× 10−4) and
stearic saturated FAs (OR: 1.17, 95% CI: 1.01–1.35, P=0.041) were
associated with increased CRC risk, whilst oleic (OR: 0.77, 95% CI:
0.65–0.92, P=3.9×10−3) and palmitoleic (OR: 0.36, 95% CI:
0.15–0.84, P=0.018) monounsaturated FAs, and linoleic poly-
unsaturated FAs (OR: 0.95, 95% CI: 0.93–0.98, P=3.7×10−4) were
associated with reduced CRC risk. In the analysis by May-Wilson et al.
(2017), the same SNP (rs102275), or a correlated SNP (rs174547), was
used to infer causal relationships between multiple FAs and risk of CRC.
These SNPs were used assuming that the exposure individually accounts
for the eﬀect on CRC, and the eﬀect of the genetic variant on CRC risk is
therefore counted twice, in that it is assigned to multiple FA exposures
(Holmes et al., 2017). Consequently, such single locus MR analyses are
unable to determine which FA primarily drives the relationship be-
tween FA proﬁle and CRC risk.
Chronic inﬂammation has been identiﬁed as a risk factor for CRC
(Grivennikov, 2013). Higher concentrations of C-reactive protein
(CRP), a marker of inﬂammation, have been associated with an in-
creased risk of CRC in observational epidemiological studies (Tsilidis
et al., 2008). Considering only observational studies it is unclear
however whether this relationship is causal, or a result of confounding
factors. Wang et al. (2018) conducted the largest MR analysis of CRP
concentration and CRC risk to-date, and failed to ﬁnd evidence that
CRP concentrations are causally related to risk of CRC. Nimptsch et al.
(2015a) conversely found a positive relationship between CRP con-
centrations and CRC risk (OR: 1.74, 95% CI: 1.06–2.85). However, the
study by Nimptsch et al. (2015a) considered only 727 CRC cases and
727 controls, whilst Wang et al. (2018) used data from 30,480 CRC
cases and 22,844 controls. This suggests that the causal relationship
reported by Nimptsch et al. (2015a) may be a false positive.
Numerous studies have associated height with increased risk of
cancers, including breast, CRC, leukemia, non-Hodgkin lymphoma and
malignant melanoma (Green et al., 2011). GWAS of height encom-
passing more than half a million individuals have been conducted,
identifying SNPs that explain a substantial proportion of height varia-
tion (Yengo et al., 2018), and MR frameworks are therefore well suited
to investigate the causal relationship between height and CRC. Using
data from 10,226 CRC cases and 10,286 controls, Thrift et al. (2015a)
found a positive association between height and CRC risk (OR: 1.07,
95% CI: 1.01–1.14). In a smaller study of 5100 cases and 4831 controls,
Khankari et al. (2016) also reported a positive association (OR: 1.58,
95% CI: 1.14–2.18, P=0.006).
Epidemiological studies of the eﬀect of reproductive factors on risk
of CRC have not been consistent (Martinez et al., 1997; Tsilidis et al.,
2010). Neumeyer et al. (2018) employed MR frameworks to study the
eﬀect of age at menarche and age at menopause on CRC risk, using data
from 12,944 women diagnosed with CRC, and 10,741 women without
CRC, identifying no signiﬁcant associations. The SNPs used as IVs for
these reproductive factors explain only a small proportion of their
variance however, and therefore although this study used data from a
large number of CRC cases and controls, it had limited power to detect
weak causal eﬀects. Nevertheless, these results suggest that it is un-
likely that age at menarche and menopause have substantial causal
eﬀects on CRC risk.
Polymorphisms altering the conversion rates of alcohol-metabo-
lizing enzymes, leading to a build-up of excess acetaldehyde and
thereby reducing heavy alcohol use, are prevalent in certain Asian
populations (Eng et al., 2007). These polymorphisms, such as
Glu487Lys in ALDH2, therefore oﬀer the opportunity to use MR fra-
meworks to investigate the eﬀect of alcohol consumption on various
traits. Wang et al. (2011) conducted a meta-analysis of MR studies using
the Glu487Lys polymorphism to examine the relationship between al-
cohol consumption and risk of CRC, ﬁnding higher genetically pre-
dicted alcohol intake to be associated with increased CRC risk (OR:
1.31, 95% CI: 1.01–1.70). The lower frequency of these enzyme-al-
tering alleles in non-Asian populations limits the use of MR to study risk
factors in other groups. Large projects such as UK Biobank, which has
genotyped SNPs and collected data on alcohol consumption in ap-
proximately 500,000 individuals (Bycroft et al., 2018), have led to the
identiﬁcation of SNPs associated with alcohol intake common in other
populations (Clarke et al., 2017). Additional alcohol-associated SNPs
will facilitate the wider use of MR frameworks to study the eﬀect of
alcohol consumption on disease risk.
Dimitrakopoulou et al. (2017) used an MR strategy to investigate
the relationship between vitamin D and the risk of seven cancers, in-
cluding CRC, employing SNPs associated with circulating 25-
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hydroxyvitamin D (25-OHD) as IVs. The analysis found little evidence
that vitamin D was associated with increased risk of any of the cancers.
He et al. (2018) and Theodoratou et al. (2012) both also similarly found
non-signiﬁcant associations between circulating 25-OHD and CRC risk.
These data do not support the results of observational epidemiological
studies, which have found circulating 25-OHD to be associated with
decreased CRC risk (Ma et al., 2011), suggesting that the observational
studies could be biased by reverse causality or confounding factors.
Interleukin-6 (IL-6) is thought to inﬂuence the progression of sev-
eral forms of cancer (Kumari et al., 2016). An MR analysis of circulating
IL-6 concentrations and cancer risk was performed by Tian et al.
(2015), who did not ﬁnd evidence of a causal relationship. This is
concordant with the results of observational epidemiological studies,
which have also not identiﬁed IL-6 concentrations to be associated with
CRC risk (Zhou et al., 2014).
One of the earliest studies to use an MR framework to investigate
CRC risk factors was conducted by Lin et al. (2002), who used a poly-
morphism in PTGS2 (Val511Ala) to simulate the eﬀects of aspirin, and
thereby study the relationship between aspirin use and CRC risk. Non-
signiﬁcant negative associations between the aspirin-simulating allele
and CRC risk were reported, although the study sample sizes were
small. The Val511Ala polymorphism is not common in some popula-
tions, including Chinese, Japanese and Caucasians, prohibiting its study
in many large GWAS data sets based on these ethnicities (Lin et al.,
2002).
The causal relevance of telomere length to various cancers has also
been interrogated using MR frameworks. Whilst two MR studies found
genetically predicted longer telomeres to be associated with increased
risk of some cancers, including glioma and lung, no association with
CRC risk was identiﬁed (Telomeres Mendelian Randomization
Collaboration et al., 2017; Zhang et al., 2015). Retrospective observa-
tional studies of telomere length and CRC found individuals diagnosed
with CRC to have shorter telomeres (Pooley et al., 2010), whilst a
prospective study identiﬁed no signiﬁcant association between telo-
mere length and CRC diagnosis (Zee et al., 2009). The results from the
prospective study and MR studies suggest that the inverse relationship
identiﬁed in the retrospective study is likely due to reverse causation
(Fernandez-Rozadilla et al., 2018; Pooley et al., 2010).
6. Future uses of Mendelian randomisation
Whilst MR has provided supporting evidence for a number of known
and suspected CRC risk factors (Table 1), there are many other putative
CRC risk factors that have not yet been interrogated using MR frame-
works, including coﬀee consumption and intake of foods containing
calcium, iron or zinc (World Cancer Research Fund, 2017). For some
exposures, a lack of associated SNPs explaining a substantial proportion
of variance prevents their consideration. As GWAS sample sizes con-
tinue to increase, the number of exposures for which there is suﬃcient
power to identify small or moderate eﬀect sizes under an MR frame-
work will grow.
So far, MR analyses of CRC risk have generally been hypothesis-
driven (i.e. have considered exposures for which there is pre-existing
evidence for an eﬀect on CRC risk). Hypothesis-free MR has the po-
tential to identify previously unsuspected risk factors not considered in
observational epidemiological studies (Evans and Davey Smith, 2015).
Tools such as MR-Base (Hemani et al., 2018), which provides MR
method implementations and databases of collated GWAS summary
statistics, could help facilitate such hypothesis-free scans.
The development and application of additional techniques will also
help robustly infer causality between exposures and CRC risk, whilst
avoiding biases that can lead to false positives. GSMR improves upon
the power of other summary-data-based MR methods by accounting for
linkage disequilibrium between SNPs (Zhu et al., 2018), thereby
avoiding the unnecessary loss of information. LCV models can identify
causal relationships between genetically correlated traits, mediating
such correlations with latent causal variables (O'Connor and Price,
2018). This reduces the number of false positives that can occur when
using other summary-data-based MR approaches with genetically cor-
related traits (O'Connor and Price, 2018).
7. Conclusion
Mendelian randomisation has provided evidence supporting, and
not supporting, the causal relationship between multiple risk factors
and CRC. Further study using MR frameworks will help inform public
health strategies, as well as provide better understanding of CRC ae-
tiology.
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